Anthropic launches Claude Science as flagship research product
SkimNews Take
A standalone product for autonomous science research marks a shift from general-purpose assistant to vertical application; focusing on diseases the source labels "neglected" lets Anthropic's own use of the tool double as capability demonstration and public-benefit work.
Get the Tech newsletter
Daily tech — startups, AI labs, chips, the launches that shape the next decade. Free.
- Anthropic unveiled Claude Science at a Tuesday event for pharma executives, biotech founders, and researchers, positioning it as a full-featured, standalone product alongside Claude Code and Claude Cowork and making it available to all paid Claude subscribers.
- Claude Science is designed to autonomously carry out research work, help scientists run code on powerful computer clusters, and prioritize reproducibility, with tools particularly useful for computational biology and drug development.
- John Jumper, the DeepMind researcher who shared the Nobel Prize in Chemistry for AlphaFold, announced earlier this month that he is leaving DeepMind for Anthropic — a major scientific endorsement for the company.
- Harvard physicist Matthew Schwartz estimated, based on his work with Anthropic's tools, that the company's Opus 4.5 model is "about as capable of executing scientific projects as a second-year graduate student."
- Alexander Tarashansky, who led Claude Science's development, demonstrated the system autonomously identifying new drug candidates for phenylketonuria, a rare genetic disease.
- Anthropic will use Claude Science to pursue its own research into drug candidates for neglected diseases, not just sell the product to pharma companies and university labs.
- Anthropic says it is set to see its first profitable quarter ahead of a potential IPO later this year, and pharmaceutical contracts could help sustain profitability as the "tokenmaxxing craze" cools.
Why it matters: Anthropic is making a direct play for Google DeepMind's decade-long dominance in AI for science, and the launch lands alongside Nobel laureate John Jumper's defection from DeepMind. With a profitable quarter and IPO on the horizon, pharma contracts could anchor Anthropic's revenue as broader LLM demand normalizes.
